Secukinumab treatment sustains patient-reported outcome benefits through 1 year
Alison J. Gottlieb, Peter Foley(The University of Melbourne), Thomas G. Fox(Emory University), Bintu Sherif(RTI Health Solutions), UG Mallya
Unknown
April 30, 2015
Cited by 0
Related Papers
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus
|Journal of the American Academy of Dermatology|2006|654
A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix®) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study
|Journal of Dermatological Treatment|2003|286
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
|Journal of the American Academy of Dermatology|2019|257
Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial
|British Journal of Dermatology|2014|221
A prospective study of the use of cryosurgery for the treatment of actinic keratoses
|International Journal of Dermatology|2004|182